Fluidic Analytics Ltd, a Cambridge, UK-based developer of characterizing proteins, raised $31m in funding.
The round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus Capital Partners.
The company intends to use the funds to continue the commercial roll-out of its lab-tools pipeline and to develop further clinical applications of its technology.
Led by Andrew Lynn, CEO, Fluidic Analytics leverages a proprietary technology platform from the University of Cambridge designed explicitly to give deep insights into the way that proteins fold, aggregate and interact by characterizing them in solution – precisely as they exist in the body.
These products have the potential to allow researchers to understand the mechanisms underlying conditions like Alzheimer’s disease, pharmaceutical companies to develop effective drugs, and patients to gain access to accurate diagnostics in the clinic, at the pharmacy or at home.